EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Strategies for Spinocerebellar Ataxia Type 1

Laurie M C Kerkhof iD, Bart P C van de Warrenburg iD, Willeke M C van Roon-Mom iD, Ronald A M Buijsen iD

Biomolecules · 2023

DOI: 10.3390/biom13050788 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2023. Verfasst von Laurie M C Kerkhof und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. Hauptthemen laut MEDLINE: Cerebellum, Spinocerebellar Ataxias. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch brain foundation, ZonMW PSIDER project, ZonMw Pto2.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

: Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder that affects one or two individuals per 100,000. The disease is caused by an extended CAG repeat in exon 8 of the ATXN1 gene and is characterized mostly by a profound loss of cerebellar Purkinje cells, leading to disturbances in coordination, balance, and gait. At present, no curative treatment is available for SCA1. However, increasing knowledge on the cellular and molecular mechanisms of SCA1 has led the way towards several therapeutic strategies that can potentially slow disease progression. SCA1 therapeutics can be classified as genetic, pharmacological, and cell replacement therapies. These different therapeutic strategies target either the (mutant) ATXN1 RNA or the ataxin-1 protein, pathways that play an important role in downstream SCA1 disease mechanisms or which help restore cells that are lost due to SCA1 pathology. In this review, we will provide a summary of the different therapeutic strategies that are currently being investigated for SCA1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CerebellumSpinocerebellar AtaxiasHumansAtaxin-1Purkinje Cells

Stichwörter der Autor:innen

ATXN1Spinocerebellar ataxia type 1ataxin1clinical trialsgain-of-function mechanismneurodegenerative disorderpolyQ disorderspreclinical researchtherapeutic strategies

Substanzen

Ataxin-1

Autor:innen und Institutionen

  • Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Dutch Center for RNA Therapeutics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.

ORCID-Profile: Laurie M C Kerkhof, Bart P C van de Warrenburg, Willeke M C van Roon-Mom, Ronald A M Buijsen

Förderung

  • Dutch brain foundation
  • ZonMW PSIDER project
  • ZonMw Pto2

Zitieren

APA

Kerkhof, L. M. C., van de Warrenburg, B. P. C., van Roon-Mom, W. M. C., & Buijsen, R. A. M. (2023). Therapeutic Strategies for Spinocerebellar Ataxia Type 1. Biomolecules. https://doi.org/10.3390/biom13050788

Vancouver

Kerkhof LMC, van de Warrenburg BPC, van Roon-Mom WMC, Buijsen RAM. Therapeutic Strategies for Spinocerebellar Ataxia Type 1. Biomolecules. 2023. doi:10.3390/biom13050788

BibTeX
@article{Kerkhof2023,
  author = {Kerkhof, Laurie M C and van de Warrenburg, Bart P C and van Roon-Mom, Willeke M C and Buijsen, Ronald A M},
  title = {Therapeutic Strategies for Spinocerebellar Ataxia Type 1},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13050788}
}
Kostenlos starten →